NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.

Meena S. Moran, MD
Jennifer Barsky Reese, PhD
Laura H. Rosenberger, MD, MS
Patricia Robinson, MD

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Tarah Ballinger, MD
Novartis Pharmaceuticals Corporation: Honoraria

William J. Gradishar, MD
AstraZeneca Pharmaceuticals LP: Honoraria; Scientific Advisor
Daiichi-Sankyo Co.: Honoraria; Scientific Advisor
Eli Lilly and Company: Scientific Advisor

Heather A. Parsons, MD, MPH
AstraZeneca Pharmaceuticals LP: Consulting Fee
Daiichi-Sankyo Co.: Consulting Fee
Guardant Health: Honoraria

Elena Ratner, MD, MBA
Aspira: Scientific Advisor
Zai Labs: Scientific Advisor

Cesar A. Santa-Maria, MD, MSCI
AstraZeneca Pharmaceuticals LP: Grant/Research Support
Bristol Myers Squibb: Grant/Research Support
Celldex Therapeutics: Grant/Research Support
Merck & Co., Inc.: Grant/Research Support
Novartis Pharmaceuticals Corporation: Grant/Research Support
Pfizer Inc.: Grant/Research Support

Hatem Soliman, MD
AstraZeneca Pharmaceuticals LP: Consulting Fee
Eli Lilly and Company: Consulting Fee
Merck & Co., Inc.: Product/Speakers Bureau
Novartis Pharmaceuticals Corporation: Consulting Fee
Puma Biotechnology: Consulting Fee
SeaGen: Consulting Fee

Mei Wei, MD
AstraZeneca Pharmaceuticals LP: Scientific Advisor
Gilead Sciences, Inc.: Consulting Fee
Relay Therapeutics: Scientific Advisor

Kari B. Wisinski, MD 
AstraZeneca Pharmaceuticals LP: Consulting Fee; Grant/Research
Context Therapeutics: Grant/Research Support
Genentech, Inc.: Grant/Research Support
Gilead Sciences, Inc.: Consulting Fee
Loxo@Lilly: Consulting Fee
Novartis Pharmaceuticals Corporation: Grant/Research Support
Pfizer Inc.: Consulting Fee; Grant/Research Support
Puma Biotechnology: Grant/Research Support
Relay Therapeutics: Grant/Research Support
sanofi-aventis U.S.: Grant/Research Support
SeaGen: Grant/Research Support
Stemline Therapeutics: Consulting Fee
Zymeworks: Grant/Research Support

Eric H. Yang, MD 
Amgen: Grant/Research Support
Boehringer Ingelheim GmbH: Grant/Research Support
Bristol Myers Squibb: Grant/Research Support
CSL Behring: Grant/Research Support
Edwards Lifesciences: Consulting Fee
Eli Lilly and Company: Grant/Research Support
Pfizer Inc.: Consulting Fee
Xencor: Consulting Fee

NCCN Staff Disclosures

None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.